APYX - NASDAQ
Apyx Medical Corporation
$3.79
-0.26%Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
At a Glance
Live SnapshotApyx Medical Corporation Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Apyx Medical Corporation Cash Flow Statement
APYX • NASDAQ
| Apyx Medical Corporation Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
-11.1M | -23.6M | -18.9M | -23.3M | -15.2M | -11.9M | -19.7M | 64M | -5.1M | -4M | -5.4M | -17.3M | -4.3M | 617K | 109K | -1.5M | 595.5K | 1.8M | 2.4M | 2.7M | |
655K | 599K | 692K | 890K | 903K | 887K | 754K | 669K | 696K | 734K | 812K | 876K | 827K | 857K | 925K | 1M | 1M | 973.1K | 770.8K | 529.3K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -368K | -196K | 25K | -25K | 4M | -1.6M | 210K | -76K | -974K | 60.4K | 754K | -208.8K | 0.0 | |
2M | 4M | 5.1M | 6.7M | 5.1M | 4.2M | 3.6M | 1.5M | 871K | 809K | 575K | 388K | 506K | 161K | 132K | 163K | 136.4K | 0.0 | 0.0 | 0.0 | |
2M | 2.1M | 2.3M | 628K | 603K | 996K | 215K | -68.4M | 503K | 209K | -1.6M | 8M | 912K | -154K | 703K | 1.1M | 12K | 165.8K | -20.1K | 509.6K | |
(258K) | (382K) | (329K) | (128K) | (111K) | (82K) | (325K) | (13.3M) | (32K) | (27K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (245K) | (135.6K) | (0.0) | (0.0) | |
-1.6M | -1.2M | 5.5M | -5.2M | -1.8M | -10.3M | -3.3M | -18.4M | -516K | -664K | -157K | 3.6M | 1.2M | -1.5M | 104K | -371K | -2M | -1.5M | -906.9K | -735.8K | |
-8M | -18M | -5.2M | -20.3M | -10.4M | -16.1M | -18.5M | -21M | -3.7M | -2.8M | -5.8M | -417K | -2.5M | 165K | 1.9M | -566K | -98.3K | 742.8K | 2M | 3M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-1.1M | -722K | -533K | -1M | -723K | -581K | -1.3M | -363K | -624K | -286K | -421K | -630K | -588K | -753K | -542K | -201K | -2.5M | -4.5M | -1.7M | -2.5M | |
(0.0) | (0.0) | (7.4M) | (0.0) | (195K) | (0.0) | -80.7M | (91.1M) | (0.0) | (0.0) | -500K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -18.9M | -87.2M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 80.7M | 25.8M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | -147K | 0.0 | -195K | 0.0 | 80.7M | 29.7M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 633K | 1.2K | 10.6K | 0.0 | 0.0 | |
-1.1M | -722K | (6.7M) | -1M | -723K | -581K | (60.5M) | (29.3M) | -624K | -286K | -921K | -630K | -588K | -753K | -542K | (432K) | -2.5M | -4.5M | -1.7M | -2.5M | |
FINANCING ACTIVITIES | ||||||||||||||||||||
9.5M | 7M | 2.7M | 365K | 67K | 148K | 0.0 | 0.0 | 0.0 | 5.8M | 11.5M | 0.0 | 48K | 0.0 | 0.0 | 2.8M | 79K | 223K | 253.9K | 1.3M | |
-20K | -20K | 35M | -148K | -238K | -369K | -60K | -2.7M | -239K | -240K | -239K | -84K | -162K | -130K | -302K | -1.1M | 2.1M | 2.7M | 0.0 | -186.5K | |
60K | -235K | -5.6M | 0.0 | 195K | 148K | 207K | 202K | 60K | 184K | 1.5M | -1.3M | 0.0 | 0.0 | 0.0 | 2.8M | 231.0 | 0.0 | 0.0 | 0.0 | |
9.6M | 6.7M | 32.2M | 217K | 24K | -73K | 147K | -2.5M | -179K | 5.8M | 12.8M | -1.1M | 6.9M | -130K | -302K | 1.7M | 2.2M | 2.9M | 253.9K | 1.1M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
-466K | 113K | -191K | 395K | 103K | -177K | 3K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 89K | -503.0 | -88.5K | 0.0 | 0.0 | |
-1K | -11.9M | 33.5M | -20.7M | -11M | -16.9M | 42.2M | 5.8M | -4.5M | 2.7M | 6.1M | -2.2M | 3.8M | -718K | 1.1M | 1.7M | -409.6K | -970.3K | 581.9K | 1.7M | |
31.7M | 43.7M | 10.2M | 30.9M | 41.9M | 58.8M | 16.6M | 10.7M | 14.5M | 11.8M | 5.7M | 7.9M | 4.2M | 4.9M | 3.8M | 2.2M | 2.6M | 3.5M | 3M | 1.3M | |
31.7M | 31.7M | 43.7M | 10.2M | 30.9M | 41.9M | 58.8M | 16.5M | 9.9M | 14.5M | 11.8M | 5.7M | 7.9M | 4.2M | 4.9M | 3.8M | 2.2M | 2.6M | 3.5M | 3M | |
-9.1M | -18.8M | -5.8M | -21.3M | -11.2M | -16.6M | -19.8M | -21.4M | -4.3M | -3.1M | -6.2M | -1M | -3.1M | -588K | 1.4M | -767K | -2.6M | -3.8M | 328K | 511.2K |
SEC Filings
APYX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 21, 2026 | May 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 10, 2026 | March 10, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 10, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 12, 2025 | December 08, 2025 | 2025 | |
S-3 S-3 N/A | December 01, 2025 | December 01, 2025 |
Related Guides
Continue your APYX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.